BRAF and melanoma: Autophagy has been found to contribute to acquired resistance to targeted therapies in BRAF V600-mutant melanoma [39], which has led to interest in targeting autophagy pathways as a strategy to improve outcomes in BRAF V600-mutant melanoma.